Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Cancer Related Cognitive Decline: early-phase trial registry

1 of 1 indexed Cancer Related Cognitive Decline trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Cancer Related Cognitive Decline: 1 US clinical trial tracked, 1 recruiting.

Cancer Related Cognitive Decline is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Georgetown University, running 1 of these trials.

Enrollment posture brief

Registry condition cancer-related-cognitive-decline

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Cancer Related Cognitive (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Cancer Related Cognitive Decline

Cancer Related Cognitive Decline lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cancer Related Cognitive Decline on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cancer Related Cognitive Decline is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Cancer Related Cognitive Decline records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Chemotherapy regimen that includes ddAC Drug
1 trials
TCHP Drug
1 trials
TC Drug
1 trials
ddAC/ddT Drug
1 trials
TTP488 Drug
1 trials

US sites by state

Facility locations filed on Cancer Related Cognitive Decline trials. A trial with sites in several states counts in each.

New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cancer Related Cognitive Decline page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Cancer Related Cognitive Decline trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Georgetown University sponsors the most Cancer Related Cognitive Decline trials on record, review their full trial history before evaluating a specific study. See Georgetown University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer Related Cognitive Decline condition card totals 1 registered trials; most-linked intervention Chemotherapy regimen that includes ddAC; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.